Investment Analysts’ Recent Ratings Changes for Attovia Therapeutics (ATTO)
A number of research firms have changed their ratings and price targets for Attovia Therapeutics (NASDAQ: ATTO): 9/4/2026 – Attovia Therapeutics was upgraded by Zacks Research to “hold”. 8/31/2026 – Attovia Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $45.00 price target on the stock. 8/31/2026 – Attovia Therapeutics […]
16 Sep 10:56 · The Cerbat Gem